MERCK KGAA SPNS/ADR (MKKGY)
MKKGY moved a median of +0.04% 30 minutes after news, and +0.06% by the close. How MKKGY actually reacts to news — the realized, point-in-time move the market made, measured across 65 labeled events over the last three years with zero look-ahead.
MKKGY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 62 |
| 30-min | +0.04% | 52% | 65 |
| 60-min | +0.08% | 57% | 65 |
| to close | +0.06% | 54% | 65 |
| Middle 50% of MKKGY reactions | -0.26% to +0.35% |
|---|---|
| Median reaction (30-min) | +0.04% |
| Measured reactions | 65 |
Half of all MERCK KGAA SPNS/ADR news events land between -0.26% and +0.35% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MKKGY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MKKGY's baseline. Nothing else.
Recent MKKGY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| MilliporeSigma Announces Opening of BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe | Press release | GlobeNewswire | -0.41% | -0.63% | |
| EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations | Press release | Business Wire | +0.07% | -0.13% | |
| EMD Serono Announces Healthcare Leadership Changes for Global Commercial Strategy and North America | Press release | Business Wire | +0.48% | +1.53% | |
| MilliporeSigma Announces Hiba Therapeutics as Winner of 2026 North American Advance Biotech Grant | Press release | GlobeNewswire | +0.48% | +1.53% | |
| Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies | Press release | Business Wire | +0.36% | +0.62% | |
| MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & Business Development | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer | Press release | Business Wire | +0.00% | +1.54% | |
| MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies | Press release | GlobeNewswire | -0.10% | -1.65% | |
| Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations | Press release | Business Wire | +0.35% | +1.29% | |
| MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography | Press release | GlobeNewswire | +0.00% | -0.40% | |
| MilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio | Press release | GlobeNewswire | -0.04% | -0.23% | |
| MilliporeSigma Marks 10 Years of SPARK™ Mobilizing Employee Volunteers to Help Inspire the Next Generation in STEM | Press release | GlobeNewswire | +0.08% | -0.92% | |
| EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities | Press release | Business Wire | +0.00% | +1.51% | |
| FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor | Press release | Business Wire | -0.05% | +0.15% | |
| EMD Serono Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis | Press release | Business Wire | +0.00% | +1.36% | |
| MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies | Press release | Business Wire | +0.34% | -0.49% | |
| Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT | Press release | Business Wire | -0.06% | +2.20% | |
| EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies | Press release | Business Wire | +0.29% | -0.62% | |
| MilliporeSigma to Acquire Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio | Press release | Business Wire | +0.03% | -0.38% | |
| EMD Serono to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025 | Press release | Business Wire | +0.39% | -0.16% | |
| MilliporeSigma and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration | Press release | Business Wire | +0.00% | +1.70% | |
| MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation | Press release | Business Wire | -0.01% | -1.17% | |
| MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant | Press release | Business Wire | +0.00% | -0.59% | |
| EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 | Press release | Business Wire | +0.15% | +0.37% | |
| Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor | Press release | Business Wire | +0.37% | -1.32% | |
| EMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025 | Press release | Business Wire | +0.12% | +0.08% | |
| EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash | Press release | Business Wire | +0.08% | -0.33% | |
| Curiosity Cube 2025: MilliporeSigma’s Mobile Science Labs Tour Globally to Bring STEM Education to Students | Press release | Business Wire | -0.06% | +2.77% | |
| MilliporeSigma Partners with Opentrons Labworks, Inc., Supporting Lab of the Future | Press release | Business Wire | -0.14% | +0.38% | |
| MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio | Press release | Business Wire | +0.00% | +1.06% | |
| MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio | Press release | Business Wire | +0.37% | -0.78% | |
| EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business | Press release | Business Wire | — | -0.15% | |
| Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial | Press release | Business Wire | +1.19% | +0.22% | |
| MilliporeSigma Invests $76 Million to Expand ADC Manufacturing for Novel Cancer Therapies | Press release | Business Wire | -0.06% | -0.36% | |
| MilliporeSigma Opens New €290 Million Biosafety Testing Facility in Rockville, Maryland, USA | Press release | Business Wire | +0.00% | +0.27% | |
| EMD Serono Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity | Press release | Business Wire | +0.00% | +0.29% | |
| MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing | Press release | Business Wire | +0.00% | +0.56% | |
| MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media Manufacturing | Press release | Business Wire | +0.00% | -1.42% | |
| Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG) | Press release | Business Wire | +0.00% | +0.05% | |
| MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering | Press release | Business Wire | +0.00% | +0.22% | |
| MilliporeSigma and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s Research | Press release | Business Wire | +0.00% | +0.06% | |
| MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant | Press release | Business Wire | -0.06% | +0.23% | |
| Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment | Press release | Business Wire | -0.04% | +0.58% | |
| MilliporeSigma Launches First Software for Complete Data Traceability in Microbial Quality Control | Press release | Business Wire | — | -0.18% | |
| EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024 | Press release | Business Wire | +0.03% | +0.47% | |
| MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing | Press release | Business Wire | — | -0.40% | |
| MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour | Press release | Business Wire | +0.16% | -0.41% | |
| MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing | Press release | Business Wire | +0.00% | +0.19% | |
| MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea | Press release | Business Wire | +0.09% | +1.45% | |
| EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits | Press release | Business Wire | +0.00% | -1.16% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MKKGY section they belong to.
Where else MKKGY is measured.
MKKGY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EASTGATE BIOTECH CORP (ETBI) | 65 | 0.00% | 39% |
| Extendicare Inc (EXE_TSE) | 65 | -0.27% | 29% |
| CSL LTD SP/ADR (CSLLY) | 64 | +0.05% | 56% |
| Spectral Medical Inc (EDT_TSE) | 63 | 0.00% | 38% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MERCK KGAA SPNS/ADR's median reaction calculated?
Every labeled MKKGY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 65 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of MKKGY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MKKGY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.